December 19, 2012 — The first patient has been enrolled in the Boston Scientific EVOLVE II clinical trial, which is designed to further assess the safety and effectiveness of the Synergy stent system and support U.S. Food and Drug Administration (FDA) and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.

New streamlined guidelines will help healthcare providers better treat patients with the most severe type of heart attacks, according to an American Heart Association/American College of Cardiology statement.

Merit Medical Systems Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the One Snare Endovascular Snare System.

BioControl Medical has announced that the pilot clinical study of its CardioFit vagus nerve stimulation system has been recognized as seminal original research in the European Journal of Heart Failure. According to a recent editorial, “the highly cited open-label Phase II study [of the CardioFit] by De Ferrari et al. demonstrated for the first time that chronic vagus nerve stimulation is associated with improvements in New York Heart Association (NYHA) class, six min[ute] walk test, left ventricular ejection fraction, and systolic volumes up to 1 year, [setting] the stage for further investigations and clinical trials in this new era of device thearapy.”[1,2]

Hospitalized children who suffer cardiac arrest are nearly three times more likely to survive than they were about a decade ago, and no more likely to suffer brain impairment, according to new research in the American Heart Association journal Circulation: Cardiovascular Quality & Outcomes.

December 19, 2012 — The latest generation of diagnostic tests in development is expected to provide information that will be important to patient outcomes, potentially reducing the time to diagnosis of heart attacks by several hours. The specific performance characteristics of several troponin tests were evaluated in a new study published in Clinical Chemistry.[1]

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now